Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹12,292 Cr
Revenue (TTM)
₹2,387 Cr
Net Profit (TTM)
₹486 Cr
ROE
21.2 %
ROCE
28.3 %
P/E Ratio
25.3
P/B Ratio
4.4
Industry P/E
38.43
EV/EBITDA
17
Div. Yield
0.5 %
Debt to Equity
0
Book Value
₹229.7
EPS
₹39.6
Face value
2
Shares outstanding
122,629,148
CFO
₹1,910.10 Cr
EBITDA
₹3,242.80 Cr
Net Profit
₹2,216.41 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alivus Life Sciences
| 1.5 | -12.8 | -7.6 | 18.0 | 31.2 | -- | -- |
|
BSE Healthcare
| -4.8 | 0.7 | 4.9 | 16.7 | 27.0 | 21.5 | 10.3 |
|
BSE Mid Cap
| -2.4 | 0.3 | 10.1 | -1.3 | 28.6 | 28.7 | 15.7 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Alivus Life Sciences
| 50.1 | 56.4 | -33.4 |
|
BSE Mid Cap
| 25.8 | 45.5 | 1.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alivus Life Sciences
|
998.0 | 12,291.7 | 2,386.9 | 485.6 | 26.1 | 18.1 | 25.3 | 4.4 |
| 434.5 | 4,011.8 | 2,387.0 | 168.1 | 9.7 | 12.7 | 23.9 | 2.9 | |
| 860.7 | 14,857.3 | 1,030.0 | 305.2 | 34.9 | 29.7 | 48.7 | 13.1 | |
| 1,935.1 | 20,594.2 | 1,200.1 | 373.0 | 37.7 | 21.8 | 55.4 | 11.4 | |
| 6,499.0 | 1,72,374.1 | 9,360.0 | 2,191.0 | 27.4 | 15.3 | 78.7 | 11.5 | |
| 1,309.0 | 25,096.6 | 7,896.0 | 707.5 | 13.8 | 16.1 | 36.8 | 5.6 | |
| 12,514.0 | 15,696.6 | 1,476.8 | 260.1 | 17.5 | 13.7 | 60.3 | 10.3 | |
| 2,373.8 | 3,998.3 | 653.4 | 183.2 | 21.2 | 20.9 | 21.8 | 7.5 | |
| 223.5 | 4,928.5 | 6.7 | -160.8 | -2,578.1 | -106.2 | -- | 44.8 | |
| 572.9 | 4,006.1 | 2,028.9 | 150.6 | 7.5 | 6.2 | 29.1 | 1.6 |
IPO update: Glenmark Life Sciences
4 min read•By Danish Khanna
Glenmark Life Sciences IPO: Information analysis
6 min read•By Rajan Gulati and Arul Selvan
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan,... telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was incorporated in 2011 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited. Read more
Incorporated
2011
Chairman
Hiren K Patel
Managing Director
Yasir Rawjee
Group
Glenmark
Headquarters
Solapur, Maharashtra
Website
Looking for more details about Alivus Life Sciences Ltd’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Alivus Life Sciences Ltd stood at ₹ 3,411 Cr as on 31-Mar-25
The share price of Alivus Life Sciences Ltd is ₹998.00 (NSE) and ₹998.80 (BSE) as of 20-Jun-2025 10:29 IST. Alivus Life Sciences Ltd has given a return of 31.24% in the last 3 years.
Alivus Life Sciences Ltd has a market capitalisation of ₹ 12,292 Cr as on 19-Jun-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Alivus Life Sciences Ltd is 4.36 times as on 19-Jun-2025, a 37% premium to its peers’ median range of 3.19 times.
The P/E ratio of Alivus Life Sciences Ltd is 25.31 times as on 19-Jun-2025, a 34% discount to its peers’ median range of 38.43 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Alivus Life Sciences Ltd and enter the required number of quantities and click on buy to purchase the shares of Alivus Life Sciences Ltd.
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company's APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was incorporated in 2011 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
The promoter of Alivus Life Sciences Ltd is NIRMA LIMITED. NIRMA LIMITED owns 74.99 per cent of the total equity. The chairman of the company is Hiren K Patel , and the managing director is Yasir Rawjee..
There is no promoter pledging in Alivus Life Sciences Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
25,824
|
|
|
22,080
|
|
|
16,923
|
|
|
16,554
|
|
|
1,77,076
|
|
|
5,139
|
|
|
4,280
|
|
|
4,235
|
|
|
3,869
|
| Alivus Life Sciences Ltd | Ratios |
|---|---|
|
Return on equity(%)
|
18.13
|
|
Operating margin(%)
|
26.06
|
|
Net Margin(%)
|
20.06
|
|
Dividend yield(%)
|
0.5
|
Yes, TTM profit after tax of Alivus Life Sciences Ltd was ₹486 Cr.
₹-2.80
(
